Aspire Biopharma Holdings Faces Delisting Risk Due to Non-Compliance with Nasdaq Listing Rules

Strategic Insights -

Aspire Biopharma Holdings, Inc. has filed a Current Report with the U.S. Securities and Exchange Commission, disclosing its non-compliance with Nasdaq Listing Rules, threatening its continued listing on the Nasdaq Stock Market. The company's securities have been subject to delisting unless it regains compliance with the Minimum Market Value of Listed Securities (MVLS) and minimum bid price rules within a specified period. Aspire Biopharma Holdings has requested a hearing before the Nasdaq Hearings Panel to appeal the delisting determination and present its plan to regain compliance.

Key Takeaways:

  • Aspire Biopharma Holdings, Inc. received two letters from the Nasdaq Stock Market Listing Qualifications Staff, citing non-compliance with Rule 5450(b)(2)(A) and Rule 5450(a)(1), respectively.
  • The Company's Market Value of Listed Securities (MVLS) was below the minimum level of $50,000,000 for 30 consecutive trading days, triggering a 180-day compliance period to rectify the deficiency.
  • Aspire Biopharma Holdings did not regain compliance with the MVLS Rule or the Bid Price Rule within the specified period, leading to a delisting determination by the Nasdaq Staff on October 15, 2025.
  • The Company has requested a hearing before the Nasdaq Hearings Panel to appeal the delisting determination and present its plan to regain compliance with the MVLS Rule and the Bid Price Rule.
  • Aspire Biopharma Holdings has paid the associated fee of $20,000 to stay the suspension of its Common Stock and publicly traded Warrants pending the Panel's decision.
  • The Company is considering all options available to regain compliance with the MVLS Rule and the Bid Price Rule, but there can be no assurance that it will be granted an extension of time by the Panel.

Statistics:

  • Date of Report: October 17, 2025
  • Date of earliest event reported: October 15, 2025
  • Commission File Number: 001-41293
  • State or other jurisdiction of incorporation: Delaware
  • Minimum MVLS: $50,000,000
  • Minimum Bid Price: $1.00 per share
  • Compliance period: 180 days
  • Fee paid to stay suspension: $20,000

Sources:

  • Aspire Biopharma Holdings, Inc. FORM 8-K (Current Report), filed with the U.S. Securities and Exchange Commission on October 17, 2025, specifically under ITEM 3.01, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.